Literature DB >> 27422470

Primary Sellar Rhabdomyosarcoma Arising in Association With a Pituitary Adenoma.

Virginia E Duncan1, L Burt Nabors2, Paula P Warren2, Robert M Conry2, Christopher D Willey2, Arie Perry3, Kristen O Riley2, James R Hackney2.   

Abstract

Intrasellar rhabdomyosarcoma is rare, and when arising in collusion with an unrelated entity, can present a diagnostic pitfall. We describe a case of a 56-year-old woman who presented with right eye ptosis and a pituitary mass, which was resected and diagnosed as atypical pituitary adenoma. Because of residual disease and atypical pathology, the patient received adjuvant radiation. Tumor recurrence was noted after 5 months, and a second resection was performed. Nests of atypical pituitary adenoma cells within an exuberant spindle cell stroma were noted, with areas of presumed radiation necrosis. A second recurrence prompted a third resection. After expert consultation and additional immunohistochemical stains for muscle markers, a diagnosis was rendered of primary rhabdomyosarcoma arising in association with a pituitary adenoma. Despite its rarity, a high index of suspicion for rhabdomyosarcoma arising within a pituitary adenoma should be maintained in cases of atypical pituitary adenoma with a stromal response.
© The Author(s) 2016.

Entities:  

Keywords:  atypical pituitary adenoma; rhabdomyosarcoma

Mesh:

Substances:

Year:  2016        PMID: 27422470     DOI: 10.1177/1066896916658955

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  2 in total

Review 1.  Sarcomas of the sellar region: a systematic review.

Authors:  Fernando Guerrero-Pérez; Noemi Vidal; Macarena López-Vázquez; Reinaldo Sánchez-Barrera; Juan José Sánchez-Fernández; Alberto Torres-Díaz; Nuria Vilarrasa; Carles Villabona
Journal:  Pituitary       Date:  2021-02       Impact factor: 4.107

2.  Molecular Profile of a Pituitary Rhabdomyosarcoma Arising From a Pituitary Macroadenoma: A Case Report.

Authors:  Jinci Lu; Liam Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-29       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.